Display options
Cite
Friedman RJ. Benefits of novel oral anticoagulant agents for thromboprophylaxis after total hip or knee arthroplasty. Am Health Drug Benefits. 2012;5(2):115-22
Friedman, R. J. (2012). Benefits of novel oral anticoagulant agents for thromboprophylaxis after total hip or knee arthroplasty. American health & drug benefits, 5(2), 115-22.
Friedman, Richard J. "Benefits of novel oral anticoagulant agents for thromboprophylaxis after total hip or knee arthroplasty." American health & drug benefits vol. 5,2 (2012): 115-22.
Friedman RJ. Benefits of novel oral anticoagulant agents for thromboprophylaxis after total hip or knee arthroplasty. Am Health Drug Benefits. 2012 Mar;5(2):115-22. PMID: 24991315; PMCID: PMC4046449.
Copy Download .nbib Format: NLM
Share it on

Am Health Drug Benefits. 2012 Mar;5(2):115-22.

Benefits of novel oral anticoagulant agents for thromboprophylaxis after total hip or knee arthroplasty.

American health & drug benefits

Richard J Friedman

Affiliations

  1. Chairman, Department of Orthopaedic Surgery, Roper Hospital; Clinical Professor of Orthopaedic Surgery, Medical University of South Carolina, Charleston; and Medical Director of Charleston Orthopaedic Associates.

PMID: 24991315 PMCID: PMC4046449

Abstract

BACKGROUND: The incidence of venous thromboembolism (VTE) after total hip arthroplasty (THA) or total knee arthroplasty (TKA) is reduced by the use of thromboprophylactics, such as vitamin K antagonists, low-molecular-weight heparin (LMWH), or fondaparinux. However, these agents have a number of limitations that constrain their use and increase the clinical and economic burden on patients, caregivers, and healthcare resources. Effective prophylaxis may also be complicated by poor adherence to guideline recommendations.

OBJECTIVE: This article reviews the potential of newly developed oral anticoagulants to address many of the management challenges associated with vitamin K antagonists, LMWHs, and fondaparinux.

DISCUSSION: The 3 oral anticoagulants rivaroxaban, apixaban, and dabigatran have been evaluated in large phase 3 trials, and all 3 represent promising alternatives to the current standard of care. Currently, rivaroxaban is the only new oral agent to have received US Food and Drug Administration approval in the United States for prophylaxis of deep-vein thrombosis, which may lead to pulmonary embolism in patients undergoing THA or TKA. The simplified management of the new oral agents may encourage adherence with published guidelines for VTE prophylaxis and help to reduce the economic burden of VTE. Pharmacoeconomic data suggest that rivaroxaban and dabigatran may result in cost-savings when compared with enoxaparin after THA or TKA.

CONCLUSIONS: The numbers of THA and TKA surgeries are expected to increase significantly in coming years, and safer and more effective thromboprophylaxis is essential to mitigate the morbidity and mortality associated with VTE. Newly developed oral anticoagulants have the potential to address many of the limitations of current thromboprophylaxis and may reduce the cost burden associated with the management of VTE after THA or TKA.

References

  1. N Engl J Med. 2004 May 27;350(22):2257-64 - PubMed
  2. Am J Manag Care. 2002 Dec;8(12):1082-8 - PubMed
  3. Circulation. 2003 Jun 17;107(23 Suppl 1):I22-30 - PubMed
  4. J Med Econ. 2011;14(3):324-34 - PubMed
  5. Arch Intern Med. 1999 Mar 8;159(5):445-53 - PubMed
  6. N Engl J Med. 2008 Mar 6;358(10):1037-52 - PubMed
  7. N Engl J Med. 1991 Jun 27;324(26):1865-75 - PubMed
  8. Am J Orthop (Belle Mead NJ). 2010 Sep;39(9 Suppl):14-21 - PubMed
  9. Am J Manag Care. 2011 Feb;17(1 Suppl):S27-32 - PubMed
  10. Pharmacotherapy. 2009 Aug;29(8):943-53 - PubMed
  11. Ann Pharmacother. 2004 Mar;38(3):377-82 - PubMed
  12. Semin Thromb Hemost. 2011 Apr;37(3):252-66 - PubMed
  13. Curr Med Res Opin. 2008 Jan;24(1):87-97 - PubMed
  14. Manag Care. 2006 Sep;15(9):49-50, 53-60, 66 - PubMed
  15. J Bone Joint Surg Am. 2008 Jul;90(7):1598-605 - PubMed
  16. Thromb Haemost. 2011 Mar;105(3):444-53 - PubMed
  17. Pharmacoeconomics. 2003;21(7):477-96 - PubMed
  18. J Thromb Thrombolysis. 2009 Nov;28(4):465-76 - PubMed
  19. N Engl J Med. 2008 Jun 26;358(26):2765-75 - PubMed
  20. Lancet. 2009 May 16;373(9676):1673-80 - PubMed
  21. Clin Ther. 2002 Nov;24(11):1960-86; discussion 1938 - PubMed
  22. N Engl J Med. 2008 Jun 26;358(26):2776-86 - PubMed
  23. Appl Health Econ Health Policy. 2011 Nov 1;9(6):377-87 - PubMed
  24. Stroke. 2011 Dec;42(12):3594-9 - PubMed
  25. Chest. 2012 Feb;141(2 Suppl):e278S-e325S - PubMed
  26. Lancet. 2008 Jul 5;372(9632):31-9 - PubMed
  27. Chest. 2008 Jun;133(6 Suppl):234S-256S - PubMed
  28. Chest. 2008 Jun;133(6):1293-1295 - PubMed
  29. Clin Appl Thromb Hemost. 2009 Sep-Oct;15 Suppl 1:9S-16S - PubMed
  30. Lancet. 2007 Sep 15;370(9591):949-56 - PubMed
  31. J Thromb Haemost. 2003 Oct;1(10):2119-30 - PubMed
  32. Circulation. 2011 Oct 4;124(14):1573-9 - PubMed
  33. Thromb Haemost. 2010 Jun;103(6):1116-27 - PubMed
  34. Chest. 1995 Oct;108(4 Suppl):276S-290S - PubMed
  35. J Thromb Haemost. 2007 Nov;5(11):2178-85 - PubMed
  36. Lancet. 2010 Mar 6;375(9717):807-15 - PubMed
  37. N Engl J Med. 2009 Aug 6;361(6):594-604 - PubMed
  38. Am J Health Syst Pharm. 2006 Oct 15;63(20 Suppl 6):S5-15 - PubMed
  39. J Manag Care Pharm. 2004 Mar-Apr;10(2):159-65 - PubMed
  40. J Manag Care Pharm. 2007 Jul-Aug;13(6):475-86 - PubMed
  41. J Am Acad Orthop Surg. 2011 Dec;19(12):768-76 - PubMed
  42. J Vasc Surg. 2005 Oct;42(4):726-33 - PubMed
  43. N Engl J Med. 2010 Dec 23;363(26):2487-98 - PubMed
  44. Curr Med Res Opin. 2011 Feb;27(2):423-9 - PubMed
  45. Lancet. 2002 May 18;359(9319):1721-6 - PubMed
  46. J Thromb Haemost. 2004 Feb;2(2):221-7 - PubMed
  47. J Bone Joint Surg Br. 2007 Jun;89(6):799-807 - PubMed
  48. Clin Ther. 2009 Jan;31(1):194-212 - PubMed
  49. J Thromb Thrombolysis. 2006 Feb;21(1):23-9 - PubMed
  50. Thromb Haemost. 2011 Apr;105(4):721-9 - PubMed
  51. Chest. 2008 Jun;133(6 Suppl):160S-198S - PubMed
  52. N Engl J Med. 1986 Oct 9;315(15):925-9 - PubMed
  53. J Arthroplasty. 2009 Jan;24(1):1-9 - PubMed
  54. J Med Econ. 2011;14(6):824-34 - PubMed
  55. N Engl J Med. 1991 May 30;324(22):1565-74 - PubMed
  56. Chest. 2008 Jun;133(6 Suppl):381S-453S - PubMed

Publication Types